Surfactant protein C dysfunction in pediatric patients : Clinical Case
Pulmonary surfactant dysfunction disorders are caused by genetic defects that alter pulmonary surfactant metabolism. They are rare disorders and cause significant morbidity and mortality in the neonatal and pediatric populations.
OBJECTIVE: To describe the clinical, histopathological, and ultrastructural findings of the lamellar body that suggest surfactant protein C (SP-C) dysfunction, where confirmatory genetic studies are not available.
CLINICAL CASE: We report three pediatric cases of pul monary surfactant dysfunction disorders from a pediatric hospital in Peru. Video-assisted lung biop sy was performed in all cases. Ultrastructural studies of the lamellar body were compatible with type- C pulmonary surfactant dysfunction. The treatment used was methylprednisolone pulses monthly for six months, then every two months, varying the duration according to the clinical evolution. They also received daily hydroxychloroquine and azithromycin three times a week. Clinical evaluations, eye fundus, echocardiogram, electrocardiogram, and biochemistry were performed periodically. At follow-up, there was a good response to treatment and no adverse effects were observed. One case died despite the therapies received.
CONCLUSIONS: In 3 patients with type-C surfactant dysfunction, treatment with corticosteroids, hydroxychloroquine, and azithromycin was successful in 2 of them. This is one of the first case series reported in Peru that contributes to the study of these diseases, es pecially in low- and medium-income countries.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:93 |
|---|---|
| Enthalten in: |
Andes pediatrica : revista Chilena de pediatria - 93(2022), 5 vom: 31. Okt., Seite 733-740 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Disfunción de la proteína surfactante C en pacientes pediátricos: Caso Clínico |
|---|
| Beteiligte Personen: |
Nuñez-Paucar, Héctor [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 03.11.2023 Date Revised 03.11.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.32641/andespediatr.v93i5.3873 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363988289 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363988289 | ||
| 003 | DE-627 | ||
| 005 | 20231226094517.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.32641/andespediatr.v93i5.3873 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1213.xml |
| 035 | |a (DE-627)NLM363988289 | ||
| 035 | |a (NLM)37906894 | ||
| 035 | |a (PII)S2452-60532022005001206 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Nuñez-Paucar, Héctor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surfactant protein C dysfunction in pediatric patients |b Clinical Case |
| 246 | 3 | 3 | |a Disfunción de la proteína surfactante C en pacientes pediátricos: Caso Clínico |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.11.2023 | ||
| 500 | |a Date Revised 03.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Pulmonary surfactant dysfunction disorders are caused by genetic defects that alter pulmonary surfactant metabolism. They are rare disorders and cause significant morbidity and mortality in the neonatal and pediatric populations | ||
| 520 | |a OBJECTIVE: To describe the clinical, histopathological, and ultrastructural findings of the lamellar body that suggest surfactant protein C (SP-C) dysfunction, where confirmatory genetic studies are not available | ||
| 520 | |a CLINICAL CASE: We report three pediatric cases of pul monary surfactant dysfunction disorders from a pediatric hospital in Peru. Video-assisted lung biop sy was performed in all cases. Ultrastructural studies of the lamellar body were compatible with type- C pulmonary surfactant dysfunction. The treatment used was methylprednisolone pulses monthly for six months, then every two months, varying the duration according to the clinical evolution. They also received daily hydroxychloroquine and azithromycin three times a week. Clinical evaluations, eye fundus, echocardiogram, electrocardiogram, and biochemistry were performed periodically. At follow-up, there was a good response to treatment and no adverse effects were observed. One case died despite the therapies received | ||
| 520 | |a CONCLUSIONS: In 3 patients with type-C surfactant dysfunction, treatment with corticosteroids, hydroxychloroquine, and azithromycin was successful in 2 of them. This is one of the first case series reported in Peru that contributes to the study of these diseases, es pecially in low- and medium-income countries | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Protein C |2 NLM | |
| 650 | 7 | |a Pulmonary Surfactant-Associated Protein C |2 NLM | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 700 | 1 | |a Valera-Moreno, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Atamari-Anahui, Noé |e verfasserin |4 aut | |
| 700 | 1 | |a Zamudio-Aquise, Mariela Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Torres-Salas, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Lipa-Chancolla, Roxana |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Garfias, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Ponce, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Untiveros-Tello, Alex |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Andes pediatrica : revista Chilena de pediatria |d 2021 |g 93(2022), 5 vom: 31. Okt., Seite 733-740 |w (DE-627)NLM326542140 |x 2452-6053 |7 nnns |
| 773 | 1 | 8 | |g volume:93 |g year:2022 |g number:5 |g day:31 |g month:10 |g pages:733-740 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.32641/andespediatr.v93i5.3873 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 93 |j 2022 |e 5 |b 31 |c 10 |h 733-740 | ||